These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18232183

  • 1. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
    Singh KP, Periyandavar I, Rajadhyaksha GC, Jayaram S, Mishra AB, Kinagi S, Sharma A, Baliga VP.
    J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 4. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
    Yokoyama H, Kannno S, Ishimura I, Node K.
    Metabolism; 2007 Nov; 56(11):1458-63. PubMed ID: 17950094
    [Abstract] [Full Text] [Related]

  • 5. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 6. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 8. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 9. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 10. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 11. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
    Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S.
    Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503
    [Abstract] [Full Text] [Related]

  • 12. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ, Spencer CM.
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB, Fonseca VA, Truitt KE, Jones MR.
    Arch Intern Med; 2008 Jul 28; 168(14):1531-40. PubMed ID: 18663165
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
    Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD.
    Diabetes Res Clin Pract; 2009 Jan 28; 83(1):106-16. PubMed ID: 19097665
    [Abstract] [Full Text] [Related]

  • 15. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW.
    Int J Clin Pract; 2005 Oct 28; 59(10):1218-28. PubMed ID: 16178991
    [Abstract] [Full Text] [Related]

  • 16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 28; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 17. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 28; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 18. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep 28; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
    Scott R, Wu M, Sanchez M, Stein P.
    Int J Clin Pract; 2007 Jan 28; 61(1):171-80. PubMed ID: 17156104
    [Abstract] [Full Text] [Related]

  • 20. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
    Goda T, Suruga K, Komori A, Kuranuki S, Mochizuki K, Makita Y, Kumazawa T.
    Br J Nutr; 2007 Oct 28; 98(4):702-10. PubMed ID: 17537288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.